Key result
Aging drives cardiovascular and cerebrovascular diseases via p66Shc, Sirtuins, and GDF11 pathways, demanding age-tailored therapies.
Why the study?
With rapid population aging and current cardiovascular guidelines lacking age-tailored therapeutic approaches, understanding the molecular mechanisms of aging is needed to identify novel targets to counteract age-related cardiovascular and cerebrovascular disease.
Answers are grounded in this paper and cite their sources.
A better understanding of molecular aging pathways is crucial to develop age-tailored therapeutic strategies for the growing burden of cardiovascular diseases in the elderly.
Cardiovascular (CV) and cerebrovascular (CBV) diseases are recognized age-related conditions. Current guidelines underline this feature assigning to age the highest weight among any other known CV risk factor. Contributing to the ‘perfect storm’, a combination of reduced mortality and decreased fertility is supporting a demographic shift causing a gradual aging of the population worldwide. According to the World Health Organization, the population in Europe is aging rapidly; indeed, its median age is the highest worldwide, and the proportion of people aged 65 or over is set to increase from 14% in 2010 to 25% in 2050. Moreover, the number of individuals aged 80 or over is expected to raise to 40 million in 2050. Meanwhile life expectancy at birth is expected to go beyond 90 years in several European countries before 2070 (Figure 1). Life expectancy at birth worldwide and in European population. Source: United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, custom data acquired via website. Recently published data from the European Heart Journal indicate that CV and CBV diseases in Europe account for more than 4 million deaths each year (45% of total death) with large differences depending on gender and age.1 Coronary heart disease accounts for 19% of total death in men and 20% in women, While stroke-related deaths are 9 and 14%, respectively. More than 60% of all CV deaths occur in people aged 75 years or more. The average annual rate of first CV or CBV events rises from 3 per 1000 for men between 35 and 44 years of age to 74 per 1000 for those between 85 and 94 years. Thus, increasing lifespan due to improved social and health conditions is causing a ‘boomerang’ effect resulting in an increasingly aged population and a growing prevalence of age-related CV and CBV disease which, over the next decades will seriously challenge healthcare organizations. According to the American Heart Association, prevalence of CV disease will increase from 37.8 to 40.5% in the USA over the next 20 years.2 A better understanding of the effect of age on CV diseases will be crucial to counteract the ongoing epidemiological shift. To date, several age-related conditions have been clearly identified to act as determinants of CV disease.3 Among these, isolated systolic hypertension represents a key burden. In this setting, the structural vessel wall alterations characterized by increased collagen and decreased elastin content mediate aortic stiffening and lead to increased systolic and decreased diastolic blood pressure. Such conditions, increase myocardial oxygen demand (augmenting left ventricular afterload and, in chronic, left ventricular thickness) and decreases oxygen supply by reducing coronary perfusion. For this condition, low sodium intake and correct anti-hypertensive treatment (especially renin-angiotensin system inhibitors) is the recommended therapy4 however, some uncertainties remain for elderly patients. Furthermore, hypertension-induced myocardial remodelling accounts for both heart failure with preserved and reduced ejection fraction (HFpEF and HFrEF, respectively), the latter also mediated by myocardial infarction. Although these conditions strongly impair quality of life in older patients and create greater costs for healthcare systems worldwide, little is known about specific interventions that could reduce their incidence and to date, the neurohumoral axis remains the main target. Although antihypertensive treatments also showed the capacity to reduce incidence of cognitive decline and dementia in older patients, currently there is no age-tailored therapeutic approach for these patients. Frailty and sarcopenia, although not directly associated with the CV system, play an indirect role by reducing tolerance to CV therapies (both pharmacological and surgical ones). Several bodies of evidence point to inflammation as a crucial pathophysiologic component to frailty syndrome and sarcopenia. Inflammation also plays an important role in age-related calcium accumulation in various CV structures. Although already described as a systemic process, calcium accumulation becomes particularly manifest when involving the cardiac valve apparatus. Thus, although critical for survival, exaggerated inflammatory responses play an important role in CV aging. On the other hand, clinical trials evaluating the effect of anti-inflammatory drugs on primary CV prevention have not given univocal results and their utilization in daily clinical practice is still far from being implemented.5 However, body weight control and regular physical activity are amongst the non-pharmacological interventions which were shown to reduce the prevalence of such aging-related conditions. Aging gene-related cellular pathways. Complex formation of active adaptor protein p66Shc with TIM/TOM import system causes p66Shc mitochondria translocation. Active adaptor protein p66Shc, together with phosphorylated transcription factor Stat3, directly regulates opening of PTP. Complex of phosphorylated JunD with the member of the Fos family causes formation and nuclear accumulation of the AP-1 transcription complex, which regulates gene transcription. Cytoplasmic Sirt1 deacetylates different target proteins, whereas nuclear Sirt1 deacetylates histone and leads to inactivation of gene transcription. GDF11 mediates complex formation of the phosphorylated SMAD2/3 with SMAD4 and their nuclear translocation. Accumulation of active SMAD complexes directly regulates gene transcription together with other cofactors. JNK, c-Jun N-terminal kinases; ERK, extracellular signal-regulated kinases; GDF11, growth differentiation factor 11; ALK, activin receptor-like kinase; ACTR, activin receptors; SMAD, contraction of Sma and Mad (Mothers against decapentaplegic); Sirt1, silent-mating type information regulation 2 homolog 1; NAD+, nicotinamide adenine dinucleotide; TIM, transporter inner membrane; TOM, transporter outer membrane; Stat3, signal transducer and activator of transcription 3; PTP, permeability transition pore. The most evident inadequacy of current CV guidelines with respect to aging is the lack of age-tailored therapeutic approaches. In an effort to address this deficiency, a better molecular understanding of early pathogenic mechanisms mediating age-dependent CV disease e.g. endothelial dysfunction, will be vital for identifying novel therapeutic targets and strategies to cope with the approaching aging pandemic. Endothelial dysfunction is a common denominator to most CV diseases and an early step in vascular aging; it is characterized by a reduction in vasodilatory and antithrombotic properties due to decreased nitric oxide availability as well as an increased oxidative stress and inflammation. Recent years have witnessed a considerable leap forward in the understanding of molecular aging with the identification of several longevity and aging genes (Figure 2).3 Among the latter, the mitochondrial adaptor p66Shc showed important features in reactive oxygen species generation and cellular apoptosis. In fact, p66Shc deletion in mice increases lifespan by 30% and reduces stroke size after ischaemia/reperfusion brain injury. In humans, several CV risk factors such as type 2 diabetes as well as acute coronary syndrome activate this protein in peripheral blood mononuclear cells suggesting its involvement in age-related CV and CBV diseases. By modulating genes involved in oxidative stress, cell proliferation, and differentiation, the transcription factor JunD is an additional gene implicated in endothelial function. JunD deletion in young mice causes vascular senescence and premature endothelial dysfunction, whereas its overexpression in old mice displays protective features. In humans, JunD levels are reduced with aging and in specific age-related conditions (e.g. heart failure) indicating a correlation with the expression of scavenging and oxidative enzymes. The Sirtuin superfamily includes seven nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylases with different cellular localizations and functions. In humans, both Sirt1 and Sirt3 were shown to associate with lifespan. Moreover, increased Sirt1 levels showed important CV and CBV protective effects in animal models of disease by virtue of its antioxidant properties. On the other hand, low levels of Sirt1 have been reported in old people, in patients with high CV risk, and in those suffering from coronary artery disease (CAD). Furthermore, Sirt1, Sirt 3, and Sirt6 were shown to regulate cardiac hypertrophy by modulating Akt and promising preliminary results with Sirt1 natural and synthetic activators (e.g. flavonoid compounds) confirmed this gene as an attractive therapeutic target. A recently described additional longevity gene is Klotho. The correspondent protein acts blocking insulin and insulin-like growth factor 1 signalling at the cell surface and, in mice, its overexpression is protective against age-related CV disease. Although in humans’ expression levels of this gene have already showed to have a predictive value on CAD and arterial stiffness, more studies are needed to assess its potential as a target for antiaging therapies. Among age-related genes, growth differentiation factor 11 (GDF11) encoding for a TGFβ-superfamily protein with homology to myostatin has raised considerable attention. Indeed, expression of GDF11 decreases in old mice and mediates age-related cardiac hypertrophy and neurovascular diseases such as Alzheimer’s disease. Even though the very promising initial results to date, the potential of GDF11 to reverse age-related CV diseases in humans remains unexplored. The number of people suffering from age-related CV and CBV disease is increasing dramatically; therefore, there is an urgent need to develop novel therapeutic strategies to face this ongoing challenge. The different distribution of CV diseases with respect to age and sex calls for a greater effort in implementing personalized medicine. A better understanding of the features of molecular aging could directly affect our interventional capacity to delay age-related CV and CBV disease, resulting in an improved quality of life for geriatric patients and a reduced challenge for health care systems worldwide. Conflict of interest: none declared. References are available as supplementary material at European Heart Journal online.
No takes yet. Share an insight, caveat, or question.
Camici et al. (2017) conducted a review in Age-related cardiovascular and cerebrovascular diseases. Aging was evaluated. Aging is a major determinant of cardiovascular and cerebrovascular diseases, driven by molecular pathways like p66Shc, Sirtuins, and GDF11, highlighting the need for age-tailored therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: